Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01123941
Other study ID # H01_01TP
Secondary ID
Status Completed
Phase Phase 1
First received May 13, 2010
Last updated December 16, 2013
Start date May 2010
Est. completion date November 2010

Study information

Verified date December 2013
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date November 2010
Est. primary completion date June 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

1. Males and females of age =18 to =40 years.

2. Individuals who, after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.

3. Individuals in good health as determined by the outcome of medical history, physical examination, hematological / hematochemical blood tests and urinalysis and clinical judgment of the investigator.

4. If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration

Exclusion Criteria:

1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.

2. Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.

3. Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.

4. Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

5. Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days, or were in chemotherapy treatment within the past 6 months.

6. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

7. Individuals with any serious chronic or progressive disease according to judgment of the investigator.

8. Individuals who have any malignancy or lymphoproliferative disorder.

9. Individuals with history of allergy to vaccine components.

10. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.

11. Individuals who have previously received any vaccines against typhoid fever.

12. Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccine.

13. Individuals who have received blood, blood products and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.

14. Individuals with body temperature > 38.0 degrees Celsius within 3 days of intended study immunization.

15. BMI > 35 kg/m2.

16. Individuals with history of substance or alcohol abuse within the past 2 years.

17. Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.

18. Females with history of stillbirth, neonatal loss, or previous infant with anomaly.

19. Individuals who have a previously ascertained or suspected disease caused by S. Typhi.

20. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. Typhi.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Typherix
1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
NVGH Vi-CRM197
1 dose of 0.5 mL containing 25 mcg of Vi-CRM

Locations

Country Name City State
Belgium Center for the Evaluation of Vaccination (CEV) Antwerp Wilrijk (Antwerp)

Sponsors (1)

Lead Sponsor Collaborator
Novartis

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fe — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Any Post Immunization Reactions Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia and fatigue. During the 7-day period after vaccination Yes
Primary Number of Subjects Reporting Adverse Events During the 28-day period after vaccination Yes
Primary Number of Subjects Reporting Serious Adverse Events (SAEs) During the 6-month period after vaccination Yes
Secondary Anti-Vi ELISA Geometric Mean Concentration (GMC) At 28 days after vaccination No
See also
  Status Clinical Trial Phase
Completed NCT04830371 - Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants Phase 2/Phase 3
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT02324751 - Vaccines Against Salmonella Typhi Phase 2
Completed NCT01421693 - Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever Phase 4
Completed NCT05579821 - Evaluation Study of DPP® Typhoid Assay
Completed NCT02947295 - Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
Completed NCT01405521 - Understanding Typhoid Disease After Vaccination Phase 2
Completed NCT00386789 - Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age N/A
Completed NCT04801602 - Commercial Typhoid Tests Validation Trial
Recruiting NCT06104345 - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines Phase 4
Completed NCT01438996 - Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults Phase 2
Completed NCT01437267 - Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Phase 2
Completed NCT01193907 - Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) Phase 2
Recruiting NCT04349826 - The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) Phase 4
Completed NCT01608815 - Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Phase 3
Recruiting NCT05500482 - Vellore Typhoid Vaccine Impact Trial Phase 4
Completed NCT03926455 - Safety and Immunogenicity of Typhax, a Typhoid Vaccine Phase 1
Completed NCT01229176 - Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Phase 2
Completed NCT03956524 - Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Phase 1
Completed NCT04154722 - Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children Phase 4